Systematic Review of N-Acetylcysteine Supplementation in the Management of Rheumatic Diseases
Article Sidebar
Main Article Content
Abstract
Introduction: N-acetyl cysteine (NAC) has been used to treat several rheumatological conditions. The study aimed to review the use of NAC in rheumatic diseases.
Methods: PubMed/MEDLINE, EMBASE, and Scielo databases were screened for articles on NAC and rheumatic diseases until September 2023.
Results: 23 articles were found with 13,603 patients. The investigated diseases were systemic sclerosis, systemic lupus erythematosus (SLE), rheumatoid arthritis, Sjogren syndrome, bone metabolism, and a national cohort. Age varied from 17 to 64 ± 7 years old, and female gender ranged from 45.0% to 100.0% in the included articles. Disease duration ranged from 2 months to 12.1 ± 8.36 years. The NAC dosage ranged from 600 to 4,800mg/day. Concerning outcomes, the SSc articles showed improvement in digital ulcers, reduction in frequency and severity of Raynaud phenomenon, improvement in modified Rodnan skin score, reduction in pain visual analog scale, and one of them saw improvement in lung capacities. Regarding RA, all but one showed improvements in visual analog scale (VAS), health assessment questionnaire (HAQ), disease activity score- 28 joints (DAS28), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). In SLE, a reduction in SLE disease activity index (SLEDAI) and British Isles Lupus Assessment Group (BILAG) scores, glucose, CRP, and anti-dsDNA antibody levels were observed. An increase in CH50 was also seen. Unexpectedly increased risk of osteoarthritis in whom was under NAC. The side effects were mild in all studies.
Conclusion: NAC seems to be safe in treating some rheumatic conditions, especially lupus, rheumatoid arthritis, and Sjogren syndrome. Running title: NAC in rheumatic diseases.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
JHSAM publishes all articles in full open access, meaning unlimited use and reuse of articles with appropriate credit to the authors.
All our articles are published under a Creative Commons "CC-BY-NC-ND 4.0". License which permits use, distribution and reproduction in any medium,
provided that the original work is properly cited and is used for noncommercial purposes.
References
Tenório MCDS, Graciliano NG, Moura FA, Oliveira ACM, Goulart MOF. N-Acetylcysteine (NAC): impacts on human health. Antioxidants (Basel). 2021; 10(6): 967.
Wyman B, Perl A. Metabolic pathways mediate pathogenesis and offer targets for treatment in rheumatic diseases. Curr Opin Rheumatol. 2020; 32(2): 184-91.
Kim H, Cho SK, Kim JW, Jung SY, Jang EJ, Bae SC, et al. An increased disease burden of autoimmune inflammatory rheumatic diseases in Korea. Semin Arthritis Rheum. 2020; 50(3): 526-33.
Ozcamdalli M, Misir A, Kizkapan TB, Uzun E, Duygulu F, Yazici C, et al. Comparison of intra-articular injection of hyaluronic acid and N-Acetyl Cysteine in the treatment of knee osteoarthritis: a pilot study. Cartilage. 201; 8(4): 384-90.
Age MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
Correa MJ, Mariz HA, Andrade LE, Kayser C. N-acetilcisteína oral no tratamento do fenômeno de Raynaud secundário à esclerose sistêmica: ensaio clínico randomizado, placebo-controlado e duplo-cego [Oral N-acetylcysteine in the treatment of Raynaud's phenomenon secondary to systemic sclerosis: a randomized, double-blind, placebo-controlled clinical trial]. Rev Bras Reumatol. 2014; 54(6): 452-8.
Rosato E, Rossi C, Molinaro I, Giovannetti A, Pisarri S, Salsano F. Long-term N-acetylcysteine therapy in systemic sclerosis interstitial lung disease: a retrospective study. Int J Immunopathol Pharmacol. 2011; 24(3): 727-33.
Rosato E, Cianci R, Barbano B, Menghi G, Gigante A, Rossi C, et al. N-acetylcysteine infusion reduces the resistance index of renal artery in the early stage of systemic sclerosis. Acta Pharmacol Sin. 2009; 30(9): 1283-8.
Rosato E, Zardi EM, Barbano B, Menghi G, Cianci R, Amoroso A, et al. N-acetylcysteine infusion improves hepatic perfusion in the early stages of systemic sclerosis. Int J Immunopathol Pharmacol. 2009;22(3):763-72.
Rosato E, Borghese F, Pisarri S, Salsano F. The treatment with N-acetylcysteine of Raynaud's phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patients. Clin Rheumatol. 2009; 28(12): 1379-84.
Sambo P, Amico D, Giacomelli R, Matucci-Cerinic M, Salsano F, Valentini G, et al.. Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study. J Rheumatol. 2001; 28(10): 2257-62.
Salsano F, Letizia C, Proietti M, Rossi C, Proietti AR, Rosato E, et al. Significant changes of peripheral perfusion and plasma adrenomedullin levels in N-acetylcysteine long term treatment of patients with sclerodermic Raynauds phenomenon. Int J Immunopathol Pharmacol. 2005; 18(4): 761-70.
Furst DE, Clements PJ, Harris R, Ross M, Levy J, Paulus HE. Measurement of clinical change in progressive systemic sclerosis: a 1 year double-blind placebo-controlled trial of N-acetylcysteine. Ann Rheum Dis. 1979; 38(4): 356-61.
Esalatmanesh K, Jamali A, Esalatmanesh R, Soleimani Z, Khabbazi A, Malek Mahdavi A. Effects of N-acetylcysteine supplementation on disease activity, oxidative stress, and inflammatory and metabolic parameters in rheumatoid arthritis patients: a randomized double-blind placebo-controlled trial. Amino Acids. 2022; 54(3): 433-40.
Jamali F, Ahmadzadeh A, Sahraei Z, Salamzadeh J. Study of the effects of N-acetylcysteine on inflammatory biomarkers and disease activity score in patients with rheumatoid arthritis. Iran J Allergy Asthma Immunol. 2021; 20(5): 574-83.
Batooei M, Tahamoli-Roudsari A, Basiri Z, Yasrebifar F, Shahdoust M, Eshraghi A, et al. Evaluating the effect of oral N-acetylcysteine as an adjuvant treatment on clinical outcomes of patients with rheumatoid arthritis: a randomized, double-blind clinical trial. Rev Recent Clin Trials. 2018; 13(2): 132-8.
Vreugdenhil G, Swaak AJ. Effects of oral N-acetylcysteine on gold levels in rheumatoid arthritis. Br J Rheumatol. 1990; 29(5): 404-5.
Jonsson H, Wollheim FA, Svensson B. No effect of acetylcysteine on refractory rheumatoid arthritis. Clin Exp Rheumatol. 1986; 4(4): 363-4.
Abbasifard M, Khorramdelazad H, Rostamian A, Rezaian M, Askari PS, Sharifi GTK, et al. Effects of N-acetylcysteine on systemic lupus erythematosus disease activity and associated complications: a randomized double-blind clinical trial study. Trials. 2023; 24(1):129.
Garcia RJ, Francis L, Dawood M, Lai ZW, Faraone SV, Perl A. Attention deficit and hyperactivity disorder scores are elevated and respond to N-acetylcysteine treatment in patients with systemic lupus erythematosus. Arthritis Rheum. 2013; 65(5):1313-8.
Li M, Gao W, Ma J, Zhu Y, Li X. Early-stage lupus nephritis treated with N-acetylcysteine: A report of two cases. Exp Ther Med. 2015;10(2): 689-92.
Lai ZW, Hanczko R, Bonilla E, Caza TN, Clair B, Bartos A, et al. N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2012; 64(9): 2937-46.
Kudaravalli J. Improvement in endothelial dysfunction in patients with systemic lupus erythematosus with N-acetylcysteine and atorvastatin. Indian J Pharmacol. 2011; 43(3): 311-5.
Tewthanom K, Janwitayanujit S, Totemchockcyakarn K, Panomvana Na Ayudhya D. The effect of high dose of N-acetylcysteine in lupus nephritis: a case report and literature review. J Clin Pharm Ther. 2010; 35(4): 483-5.
Walters MT, Rubin CE, Keightley SJ, Ward CD, Cawley MI. A double-blind, crossover study of oral N-acetylcysteine in Sjögren's syndrome. Scand J Rheumatol Suppl. 1986; 61: 253-8.
Williamson J, Doig WM, Forrester JV, Tham MH, Wilson T, Whaley K, et al. Management of the dry eye in Sjogren's syndrome. Br J Ophthalmol. 1974; 58(9): 798-805.
Yeh YT, Liang CC, Chang CL, Hsu CY, Li PC. Increased risk of knee osteoarthritis in patients using oral N-acetylcysteine: a nationwide cohort study. BMC Musculoskelet Disord. 2020; 21(1): 531.
Sanders KM, Kotowicz MA, Nicholson GC. Potential role of the antioxidant N-acetylcysteine in slowing bone resorption in early postmenopausal women: a pilot study. Transl Res. 2007;150(4): 215.
Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. New Eng J Med. 2005; 353(21): 2229-42.
Guijarro LG, Mate J, Gisbert JP, et al. N-acetyl-L-cysteine combined with mesalamine in treating ulcerative colitis: randomized, placebo-controlled pilot study. World J Gastroenterol. 2008; 14(18): 2851-7.
Andrews NP, Prasad A, Quyyumi AA. N-acetylcysteine improves coronary and peripheral vascular function. J Am Coll Cardiol. 2001; 37(1): 117-23.
Suwannaroj S, Lagoo A, Keisler D, McMurray RW: Antioxidants suppress mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus (SLE). Lupus. 2001;10: 258-65
Lean J, Davies J, Fuller K, Jagger CJ, Kirstein B, Partington GA, et al. A crucial role for thiol antioxidants in estrogen-deficiency bone loss. J Clin Invest. 2003; 112: 915–23.
Servettaz A, Guilpain P, Goulvestre C, Chéreau C, Hercend C,Nicco C, et al. Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis.Ann Rheum Dis. 2007; 66: 1202-9.
Kelly GS. Clinical applications of N-acetylcysteine. Altern MedRev. 1998; 3: 114–27.